Finance

Lists
Q3 2026 earnings • released • EPS beat +4.92% • Revenue miss -5.38%
See results
KLBF:IDX
PT Kalbe Farma Tbk.
IDR 715.00
-0.69%
(-5.00) 1D
Nov 3, 4:06:39 PM GMT+7  ·   IDR
All symbols
SymbolPriceChange% Change
Generating top insights for KLBF...
Open
IDR 720
High
IDR 735
Low
IDR 715
Mkt. cap
33.47T
Avg. vol.
54.28M
Volume
54.99M
Dividend
2.80%
Quarterly dividend
IDR 5
Ex-dividend date
Jun 4, 2026
P/E ratio
8.99
52-wk high
IDR 1,320
52-wk low
IDR 630
EPS
IDR 80
Shares outstanding
46.81B
No. of employees
13K
Open
IDR 720
High
IDR 735
Low
IDR 715
Mkt. cap
33.47T
Avg. vol.
54.28M
Volume
54.99M
Dividend
2.80%
Quarterly dividend
IDR 5
Ex-dividend date
Jun 4, 2026
P/E ratio
8.99
52-wk high
IDR 1,320
52-wk low
IDR 630
EPS
IDR 80
Shares outstanding
46.81B
No. of employees
13K
News stories
From web sources and news partners
Profile
PT Kalbe Farma Tbk, or simply known as Kalbe, is an Indonesian pharmaceutical, healthcare and nutrition company established in 1966. The company has expanded by strategic acquisitions of pharmaceutical companies, becoming an integrated consumer health and nutrition enterprise. The Kalbe Group has brands in the prescription drugs, OTC drugs, energy drink and nutrition products, with a distribution arm that reaches over one million outlets. Notably, the company produces misoprostol, a drug which is used to treat stomach ulcers but is also widely used in Indonesia as an illegal abortifacient. Company brands in healthcare and pharmaceutical segments include Promag, Mixagrip, Woods, Komix, Diabetasol, Prenagen, Extra Joss and Fitbar. Kalbe is the largest publicly listed pharmaceutical company in Southeast Asia with around US$5 billion in market capitalization and revenues of over Rp 15 trillion. The name "Kalbe" is a syllabic abbreviation of its founder's name: Khouw Lip Boen. Wikipedia
About PT Kalbe Farma Tbk.
CEO-
Employees12.8K
FoundedSep 10, 1966
Headquarters-
SectorPharmaceutical industry
Websitekalbe.co.id
Last report
Oct 30, 2026
Fiscal period
Q3 2026
IDR 18.08 / IDR 17.23
+4.92%beat
Revenue / Est. (IDR)
9.50T / 10.04T
-5.38%miss
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in IDR
Loading Previous Earnings...
Revenue
Net income
All values in IDR
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
9.34T
9.68T
9.80T
9.50T
Cost of goods sold
5.92T
6.02T
6.25T
5.80T
Cost of revenue
5.92T
6.02T
6.25T
5.80T
Research and development expenses
160.88B
113.14B
122.60B
122.76B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.95T
2.23T
2.27T
2.59T
Operating expense
2.14T
2.33T
2.39T
2.68T
Total operating expenses
8.05T
8.36T
8.64T
8.48T
Operating income
1.28T
1.32T
1.16T
1.02T
Other non operating income
-4.17B
-3.63B
-3.74B
7.37B
EBT including unusual items
1.30T
1.36T
1.19T
1.10T
EBT excluding unusual items
1.30T
1.36T
1.18T
1.11T
Income tax expense
252.81B
303.84B
271.57B
231.04B
Effective tax rate
19.41%
22.40%
22.80%
21.08%
Other operating expenses
31.35B
-10.02B
2.13B
-36.85B
Net income
1.03T
1.03T
890.54B
817.43B
Net profit margin
11.07%
10.63%
9.09%
8.61%
Earnings per share
22.72
22.74
19.68
18.08
Interest and investment income
40.43B
32.07B
43.61B
30.89B
Interest expense
-5.77B
-4.61B
-6.78B
-20.54B
Net interest expenses
34.66B
27.46B
36.83B
10.35B
Depreciation and amortization charges
-
-
-
-
EBITDA
1.45T
1.51T
1.20T
1.21T
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps